DCR

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus irinotecan
avelumab alone vs. irinotecan 1 0.37 [0.23; 0.60], 1 RCT, I2=0%
statistically significant harm